medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2001, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2001; 48 (3)

Lipoprotein (a) and atherogenic risk in chronic hemodialysis patients

Olascoaga A, Ventura J, Tavella N, Romero C, Petraglia A, Baz A, Muñoz L, Andújar M, Garau M, Alallón W

Language: Spanish
References: 26
Page: 161-165
PDF size: 41.49 Kb.


ABSTRACT

Purpose: The lipoprotein (a) (Lp(a)) higher or equal to 30 mg/dL is considered an independent risk factor to cardiovascular disease. The atherosclerotic process of aortic stenosis and/or fibrosis aortic valvulopathy (AV), is frequent in chronic renal failure patients. The aim of this study was to assess the Lp(a) and its atherogenic risk in patients with AV in chronic hemodialysis (HDC). Methods: We analyzed 116 patients in HDC, 93 with AV diagnosed acording the American Society of Echocardiography recommendations; and 70 persons from Health Card with similar population characteristic. We assessed Lp(a) immunoturbidimetric method and total cholesterol, HDL-C, LDL-C, apolipoprotein Al and B in blood with a fast period between 9 and 12 hours. Results: In HDC Lp(a) is significative increase (p ‹ 0.05) 38 ± 33 vs 25 ± 15 mg/dL of control group. Lp(a) higher or equal to 30 mg/dL is significative increase (p ‹ 0.01) in patients with AV in HDC (52.6 vs 32.9% of control group, 54.8% in patients with AV in HDC). Conclusions: The Cardiovascular Health Study support the hypothesis that the initial lesion in AV is the same in the atherosclerosis and on both fell the same risk factors. The Lp(a) showed in patients in HDC a significative increase (p ‹ 0.01) behaving like a positive risk factor Lp(a) higher or equal to 30 mg/dL OR 1.58 (Cl 95% 1.02-2.44) to patients with AV in HDC.


REFERENCES

  1. Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 1983; 154: 357-361.

  2. Utermann G, Menzel HJ, Kraft HG, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a) concentrations in plasma. J Clin Invest 1987; 80: 458-465.

  3. Rader DJ, Brewer HB. Lipoprotein(a): Clinical approach to a unique atherogenic lipoprotein. JAMA 1992; 267: 1109-1112.

  4. Stephan PJ, Henry AC, Hebeler RF, Whiddon L, Roberts W. Comparation of age, gender, number of aortic valve cusps, concomitant coronary artery bypass grafting, and magnitude of left ventricular systemic arterial peak systolic gradient in adults, having aortic valve replacement for isolated aortic valve stenosis. Ann J Cardiol 1997; 79: 166-172.

  5. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Charaterization of the early lesion of “degenerative” valvular aortic stenosis histological and immunohistochemical studies. Circulation 1994; 90: 844-853.

  6. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in non-rheumatic stenotic aortic valves. J Ann Coll Cardiol 1994; 23: 1162-1170.

  7. Stewart F, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith DE, Kitzman DW, Otto K. The Cardiovascular Health Study. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol 1991; 14: 995-999.

  8. Mohler ER, Sheridan MJ, Nichols R, Hamey WP, Waller EF. Development and progression of aortic valve stenosis. Atherosclerosis risk factors, a causal relationship? A clinical morphological study. Clin Cardiol 1991; 14: 995-999.

  9. Gotoh T, Kuroda T, Yamasawa M. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (The JMJ Cardiac Echo and Cohort Study). Am J Card 1995; 76: 928-932.

  10. Sociedad Uruguaya de Aterosclerosis. Segundo Consenso Uruguayo sobre Dislipemias. Rev Urug Card 1998; 13: 176-204.

  11. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Krauzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986; 62: 249-257.

  12. Llach F. Cardiac calcification: dealing with another risk factor in patient with kidney failure. Seminars in Dialysis 1999; 12: 293-295.

  13. Sahn DJ, De Maria A, Kisslo J, Weiman A. Reccommendation regarding quantitation in M-mode echocardiography: Results of survery of echocardiographic measurements. Circulation 1978; 58: 1072-1083.

  14. Tietz NW. Clinical guide to laboratory test. 3a edición, Philadelphia, Pa: WB Saunders 1995: 610-611.

  15. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekman K, Kayahara N. Direct measurement of high density lipoprotein cholesterol in serum with poliethilenglicol modified enzymes and sulfated alfa-ciclodextrin. Clin Chem 1995; 41: 717-723.

  16. Friedewarld WF, Levy RS, Frederickson DS. Estimation of LDL-cholesterol concentration without use the preparafive ultracentrifuge. Clin Chem 1972; 18: 499-502.

  17. Castelli WB, Doyle JT, Gordon T. HDL cholesterol and other lipids in coronary heart disease. Circulation 1977; 55: 767-772.

  18. Tietz NW. Clinical guide to laboratory test. 3a ed. Philadelphia. Pa: WB Saunders 1995: 400-401.

  19. Martell M, Fescina R, Martínez M, Delgado L, Roca R, Barrios E. Introducción a la metodología de la investigación científica. Montevideo. Ed. Oficina del libro AEM, 1997.

  20. Lindroos M, Kupari M, Heikkila J, Tiulis R. Prevalence of aortic valve abnormalities in elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220-1225.

  21. Sprecher DL, Shaefer EJ, Kent KM, Gregg RE, Zech LA, Hoeg JM, Mc Manus B, Roberts WS, Brewer B. Cardiovascular features of homozigous familial hpercholesterolemia: Analysis of 16 patients. Am J Cardiol 1984; 54: 20-30.

  22. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.

  23. Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S. Lipoprotein(a) as a risk factor for coronary artery disease in hemodyalisis patients. Kidney Int 1999; 56(supl): 242-244.

  24. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J. Lipoprotein abnormalities in hyperlipidemic and normalipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394-1399.

  25. Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein(a) is a predictor of cardiovascular mortality of hemodialysis patients. Kidney Int 1999; 56(supl): 251-253.

  26. Suzuki S, Sato K, Tamiguchi H, Mizagawa K, Kajina M, Dohi Y, Veda R. Clinical significance of serum lipoprotein(a) in elderly patients with aortic valve sclerosis. Nippon RIZ 1998; 35(6): 444-450.




2020     |     www.medigraphic.com